BridgeMD
Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT)
EU CTIS ID: 2025-523476-23-00
What this study is testing
The primary objective is to evaluate the effect of remdesivir on neuronal injury during TBE virus infection, as measured by serum neurofilament light chain (S-NfL) levels.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Need of hospitalization at screening
- 2. Clinically suspected TBE according to ECDC definition
- 3. Hospitalization ≤ 7 days prior to start of study treatment. The 7-day period is counted as 7 full calendar days prior to the day of IMP initiation, regardless of time of hospitalization or treatment start. E.g., admission Apr 10 at 08:00 allows IMP initiation up until Apr 17 23:59.
- 4. Positive anti-TBEV IgM in blood or CSF, or detectable TBEV RNA in a clinical specimen (blood, CSF or urine) according to local test results
- 5. ≥18 years old
- 6. The patient has given their written consent to participate in the trial
You likely can't join if
- 1. Hypersensitivity to the active substances or ingredients of remdesivir or against any residues according to SmPC.
- 2. Non-Swedish speaking
- 3. Other contraindication to remdesivir treatment
- 4. Chronic kidney disease stadium 4 and 5
- 5. Pregnancy (verified by urine pregnancy test at screening)
- 6. Unable to comply with protocol requirements
See the full eligibility criteria
- 1. Need of hospitalization at screening
- 2. Clinically suspected TBE according to ECDC definition
- 3. Hospitalization ≤ 7 days prior to start of study treatment. The 7-day period is counted as 7 full calendar days prior to the day of IMP initiation, regardless of time of hospitalization or treatment start. E.g., admission Apr 10 at 08:00 allows IMP initiation up until Apr 17 23:59.
- 4. Positive anti-TBEV IgM in blood or CSF, or detectable TBEV RNA in a clinical specimen (blood, CSF or urine) according to local test results
- 5. ≥18 years old
- 6. The patient has given their written consent to participate in the trial
- 1. Hypersensitivity to the active substances or ingredients of remdesivir or against any residues according to SmPC.
- 2. Non-Swedish speaking
- 3. Other contraindication to remdesivir treatment
- 4. Chronic kidney disease stadium 4 and 5
- 5. Pregnancy (verified by urine pregnancy test at screening)
- 6. Unable to comply with protocol requirements
- 7. Before TBE-diagnosis, diagnosed with dementia or other chronic cognitive dysfunction.
- 8. Treatment or disease which, according to the investigator, can affect treatment or trial results.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.